Catherine Fleener

1.1k total citations
25 papers, 609 citations indexed

About

Catherine Fleener is a scholar working on Molecular Biology, Immunology and Epidemiology. According to data from OpenAlex, Catherine Fleener has authored 25 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Immunology and 9 papers in Epidemiology. Recurrent topics in Catherine Fleener's work include Biochemical and Molecular Research (12 papers), Adenosine and Purinergic Signaling (8 papers) and Cytomegalovirus and herpesvirus research (7 papers). Catherine Fleener is often cited by papers focused on Biochemical and Molecular Research (12 papers), Adenosine and Purinergic Signaling (8 papers) and Cytomegalovirus and herpesvirus research (7 papers). Catherine Fleener collaborates with scholars based in United States, Netherlands and Sweden. Catherine Fleener's co-authors include Edwin J. Iwanowicz, Katherine A. Rouleau, Diane Hollenbaugh, Scott H. Watterson, I‐Ming Wang, Kurt A. Schalper, Shobha Potluri, Andrew B. Nixon, Ira Jacobs and T. G. Murali Dhar and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Journal of Molecular Biology.

In The Last Decade

Catherine Fleener

24 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine Fleener United States 15 227 179 164 132 93 25 609
Eva Papp United States 6 318 1.4× 124 0.7× 44 0.3× 47 0.4× 163 1.8× 7 570
Katherine A. Rouleau United States 13 221 1.0× 152 0.8× 176 1.1× 126 1.0× 88 0.9× 17 548
Neil Lineberry United States 9 340 1.5× 272 1.5× 141 0.9× 58 0.4× 46 0.5× 19 711
G. Schmid Germany 11 191 0.8× 24 0.1× 222 1.4× 55 0.4× 19 0.2× 13 446
Marie Stupecky United States 8 326 1.4× 47 0.3× 435 2.7× 25 0.2× 33 0.4× 10 562
M Selner Canada 9 309 1.4× 15 0.1× 402 2.5× 35 0.3× 91 1.0× 11 740
Aglair B. Garcia Brazil 15 212 0.9× 138 0.8× 144 0.9× 26 0.2× 29 0.3× 30 545
Emeline Cros France 12 385 1.7× 26 0.1× 191 1.2× 20 0.2× 45 0.5× 13 628
Michael Fitzgerald United States 11 600 2.6× 164 0.9× 293 1.8× 254 1.9× 42 0.5× 17 1.0k
Linda Hogarth United Kingdom 14 387 1.7× 33 0.2× 152 0.9× 31 0.2× 26 0.3× 29 666

Countries citing papers authored by Catherine Fleener

Since Specialization
Citations

This map shows the geographic impact of Catherine Fleener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Fleener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Fleener more than expected).

Fields of papers citing papers by Catherine Fleener

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Fleener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Fleener. The network helps show where Catherine Fleener may publish in the future.

Co-authorship network of co-authors of Catherine Fleener

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Fleener. A scholar is included among the top collaborators of Catherine Fleener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Fleener. Catherine Fleener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nixon, Andrew B., Kurt A. Schalper, Ira Jacobs, et al.. (2019). Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?. Journal for ImmunoTherapy of Cancer. 7(1). 99 indexed citations
2.
3.
El-Khoueiry, Anthony B., Omid Hamid, John A. Thompson, et al.. (2017). The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).. Journal of Clinical Oncology. 35(15_suppl). 3027–3027. 14 indexed citations
4.
Yamniuk, Aaron P., Anish Suri, Stanley R. Krystek, et al.. (2016). Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific Epitope. Journal of Molecular Biology. 428(14). 2860–2879. 12 indexed citations
5.
6.
Yang, Zheng, Haiqing Wang, Theodora W. Salcedo, et al.. (2015). Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699. Journal of Pharmacology and Experimental Therapeutics. 355(3). 506–515. 14 indexed citations
7.
Fraser, Stephanie, et al.. (2015). When Close is Not Close Enough: A Comparison of Endogenous and Recombinant Biomarker Stability Samples. Bioanalysis. 7(11). 1355–1360. 12 indexed citations
8.
Latek, Robert, Catherine Fleener, Edward J. Kulbokas, et al.. (2009). Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation. Transplantation. 87(6). 926–933. 81 indexed citations
9.
Watterson, Scott H., T. G. Murali Dhar, Zhongqi Shen, et al.. (2003). Novel inhibitors of IMPDH. Bioorganic & Medicinal Chemistry Letters. 13(3). 543–546. 23 indexed citations
10.
Chen, Ping, Derek Norris, T. G. Murali Dhar, et al.. (2003). Identification of novel and potent isoquinoline aminooxazole-Based IMPDH inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(7). 1345–1348. 21 indexed citations
11.
Dhar, T. G. Murali, Zhongqi Shen, Henry H. Gu, et al.. (2003). 3-Cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure–Activity relationships. Bioorganic & Medicinal Chemistry Letters. 13(20). 3557–3560. 31 indexed citations
12.
Watterson, Scott H., T. G. Murali Dhar, Shelley K. Ballentine, et al.. (2003). Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3. Bioorganic & Medicinal Chemistry Letters. 13(7). 1273–1276. 30 indexed citations
13.
Iwanowicz, Edwin J., Scott H. Watterson, Junqing Guo, et al.. (2003). Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety. Bioorganic & Medicinal Chemistry Letters. 13(12). 2059–2063. 18 indexed citations
14.
Dhar, T. G. Murali, Scott H. Watterson, Ping Chen, et al.. (2003). Quinolone-Based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues. Bioorganic & Medicinal Chemistry Letters. 13(3). 547–551. 7 indexed citations
15.
Dhar, T. G. Murali, Zhongqi Shen, Catherine Fleener, et al.. (2002). The TosMIC approach to 3-(Oxazol-5-yl) indoles: application to the synthesis of indole-based IMPDH inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(22). 3305–3308. 16 indexed citations
16.
Pitts, William J., Junqing Guo, T. G. Murali Dhar, et al.. (2002). Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase. Bioorganic & Medicinal Chemistry Letters. 12(16). 2137–2140. 31 indexed citations
17.
Watterson, Scott H., Chunjian Liu, T. G. Murali Dhar, et al.. (2002). Novel amide-based inhibitors of inosine 5′-monophosphate dehydrogenase. Bioorganic & Medicinal Chemistry Letters. 12(20). 2879–2882. 11 indexed citations
18.
Iwanowicz, Edwin J., Scott H. Watterson, Chunjian Liu, et al.. (2002). Novel guanidine-Based inhibitors of inosine monophosphate dehydrogenase. Bioorganic & Medicinal Chemistry Letters. 12(20). 2931–2934. 18 indexed citations
19.
Gu, Henry H., Edwin J. Iwanowicz, Junqing Guo, et al.. (2002). Novel diamide-Based inhibitors of IMPDH. Bioorganic & Medicinal Chemistry Letters. 12(9). 1323–1326. 17 indexed citations
20.
Kane, Stefanie A., et al.. (2000). Development of a Binding Assay for p53/HDM2 by Using Homogeneous Time-Resolved Fluorescence. Analytical Biochemistry. 278(1). 29–38. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva Papp Breakdown of academic impact, for papers by Katherine A. Rouleau Breakdown of academic impact, for papers by Neil Lineberry Breakdown of academic impact, for papers by G. Schmid Breakdown of academic impact, for papers by Marie Stupecky Breakdown of academic impact, for papers by M Selner Breakdown of academic impact, for papers by Aglair B. Garcia Breakdown of academic impact, for papers by Emeline Cros Breakdown of academic impact, for papers by Michael Fitzgerald Breakdown of academic impact, for papers by Linda Hogarth
Rankless by CCL
2026